Engineering new bone via a minimally invasive route using human bone marrow derived stromal cell aggregates, micro ceramic particles and human platelet rich plasma gel

Anindita Chatterjea, Huipin Yuan, Supriyo Chatterjea, Henk Garritsen, Auke Renard, Clemens A. van Blitterswijk, Jan de Boer

Research output: Contribution to journalArticleAcademicpeer-review

8 Citations (Scopus)
41 Downloads (Pure)

Abstract

There is a rise in the popularity of arthroscopic procedures in orthopedics. However, the majority of cell based bone tissue engineered constructs rely on solid pre-formed scaffolding materials, which require large incisions and extensive dissections for placement at the defect site. Thus, they are not suitable for minimally invasive techniques. The aim of this study was to develop a clinically relevant, easily moldable, bone tissue engineered construct (TEC), amenable to minimally invasive techniques, using human mesenchymal stromal cells (hMSC) and calcium phosphate micro particles in combination with an in-situ forming platelet rich plasma (PRP) gel obtained from human platelets. Most conventional TECs rely on seeding and culturing single cell suspensions of hMSCs on scaffolds. However, for generating TECs amenable to the minimally invasive approach, it was essential to aggregate the hMSCs in vitro prior to seeding them on the scaffolds as unaggregated MSCs did not generate any bone. 24 hours of in vitro aggregation was determined to be optimal for maintaining cell viability in vitro and bone formation in vivo. Moreover, no statistically significant difference was observed in the amount of bone formed when the TECs were implanted via an open approach or a minimally invasive route. TECs generated using MSCs from three different human donors generated new bone through the minimally invasive route in a reproducible manner, suggesting that these TECs could be a viable alternative to pre-formed scaffolds employed through an open surgery for treating bone defects.
Original languageEnglish
Pages (from-to)340-349
JournalTissue engineering. Part A
Volume19
Issue number3-4
DOIs
Publication statusPublished - 10 Oct 2013

Fingerprint

Platelet-Rich Plasma
Ceramics
Platelets
Mesenchymal Stromal Cells
Particles (particulate matter)
Bone
Gels
Plasmas
Bone and Bones
Scaffolds
Orthopedic Procedures
Tissue
Dissection
Defects
Osteogenesis
Orthopedics
Calcium phosphate
Cell Survival
Suspensions
Surgery

Keywords

  • METIS-288055
  • IR-81418

Cite this

Chatterjea, Anindita ; Yuan, Huipin ; Chatterjea, Supriyo ; Garritsen, Henk ; Renard, Auke ; van Blitterswijk, Clemens A. ; de Boer, Jan. / Engineering new bone via a minimally invasive route using human bone marrow derived stromal cell aggregates, micro ceramic particles and human platelet rich plasma gel. In: Tissue engineering. Part A. 2013 ; Vol. 19, No. 3-4. pp. 340-349.
@article{9c3613148ac44883a50bbf606b10cdc2,
title = "Engineering new bone via a minimally invasive route using human bone marrow derived stromal cell aggregates, micro ceramic particles and human platelet rich plasma gel",
abstract = "There is a rise in the popularity of arthroscopic procedures in orthopedics. However, the majority of cell based bone tissue engineered constructs rely on solid pre-formed scaffolding materials, which require large incisions and extensive dissections for placement at the defect site. Thus, they are not suitable for minimally invasive techniques. The aim of this study was to develop a clinically relevant, easily moldable, bone tissue engineered construct (TEC), amenable to minimally invasive techniques, using human mesenchymal stromal cells (hMSC) and calcium phosphate micro particles in combination with an in-situ forming platelet rich plasma (PRP) gel obtained from human platelets. Most conventional TECs rely on seeding and culturing single cell suspensions of hMSCs on scaffolds. However, for generating TECs amenable to the minimally invasive approach, it was essential to aggregate the hMSCs in vitro prior to seeding them on the scaffolds as unaggregated MSCs did not generate any bone. 24 hours of in vitro aggregation was determined to be optimal for maintaining cell viability in vitro and bone formation in vivo. Moreover, no statistically significant difference was observed in the amount of bone formed when the TECs were implanted via an open approach or a minimally invasive route. TECs generated using MSCs from three different human donors generated new bone through the minimally invasive route in a reproducible manner, suggesting that these TECs could be a viable alternative to pre-formed scaffolds employed through an open surgery for treating bone defects.",
keywords = "METIS-288055, IR-81418",
author = "Anindita Chatterjea and Huipin Yuan and Supriyo Chatterjea and Henk Garritsen and Auke Renard and {van Blitterswijk}, {Clemens A.} and {de Boer}, Jan",
year = "2013",
month = "10",
day = "10",
doi = "10.1089/ten.TEA.2012.0104",
language = "English",
volume = "19",
pages = "340--349",
journal = "Tissue engineering. Part A",
issn = "1937-3341",
publisher = "Mary Ann Liebert Inc.",
number = "3-4",

}

Engineering new bone via a minimally invasive route using human bone marrow derived stromal cell aggregates, micro ceramic particles and human platelet rich plasma gel. / Chatterjea, Anindita; Yuan, Huipin; Chatterjea, Supriyo; Garritsen, Henk; Renard, Auke; van Blitterswijk, Clemens A.; de Boer, Jan.

In: Tissue engineering. Part A, Vol. 19, No. 3-4, 10.10.2013, p. 340-349.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - Engineering new bone via a minimally invasive route using human bone marrow derived stromal cell aggregates, micro ceramic particles and human platelet rich plasma gel

AU - Chatterjea, Anindita

AU - Yuan, Huipin

AU - Chatterjea, Supriyo

AU - Garritsen, Henk

AU - Renard, Auke

AU - van Blitterswijk, Clemens A.

AU - de Boer, Jan

PY - 2013/10/10

Y1 - 2013/10/10

N2 - There is a rise in the popularity of arthroscopic procedures in orthopedics. However, the majority of cell based bone tissue engineered constructs rely on solid pre-formed scaffolding materials, which require large incisions and extensive dissections for placement at the defect site. Thus, they are not suitable for minimally invasive techniques. The aim of this study was to develop a clinically relevant, easily moldable, bone tissue engineered construct (TEC), amenable to minimally invasive techniques, using human mesenchymal stromal cells (hMSC) and calcium phosphate micro particles in combination with an in-situ forming platelet rich plasma (PRP) gel obtained from human platelets. Most conventional TECs rely on seeding and culturing single cell suspensions of hMSCs on scaffolds. However, for generating TECs amenable to the minimally invasive approach, it was essential to aggregate the hMSCs in vitro prior to seeding them on the scaffolds as unaggregated MSCs did not generate any bone. 24 hours of in vitro aggregation was determined to be optimal for maintaining cell viability in vitro and bone formation in vivo. Moreover, no statistically significant difference was observed in the amount of bone formed when the TECs were implanted via an open approach or a minimally invasive route. TECs generated using MSCs from three different human donors generated new bone through the minimally invasive route in a reproducible manner, suggesting that these TECs could be a viable alternative to pre-formed scaffolds employed through an open surgery for treating bone defects.

AB - There is a rise in the popularity of arthroscopic procedures in orthopedics. However, the majority of cell based bone tissue engineered constructs rely on solid pre-formed scaffolding materials, which require large incisions and extensive dissections for placement at the defect site. Thus, they are not suitable for minimally invasive techniques. The aim of this study was to develop a clinically relevant, easily moldable, bone tissue engineered construct (TEC), amenable to minimally invasive techniques, using human mesenchymal stromal cells (hMSC) and calcium phosphate micro particles in combination with an in-situ forming platelet rich plasma (PRP) gel obtained from human platelets. Most conventional TECs rely on seeding and culturing single cell suspensions of hMSCs on scaffolds. However, for generating TECs amenable to the minimally invasive approach, it was essential to aggregate the hMSCs in vitro prior to seeding them on the scaffolds as unaggregated MSCs did not generate any bone. 24 hours of in vitro aggregation was determined to be optimal for maintaining cell viability in vitro and bone formation in vivo. Moreover, no statistically significant difference was observed in the amount of bone formed when the TECs were implanted via an open approach or a minimally invasive route. TECs generated using MSCs from three different human donors generated new bone through the minimally invasive route in a reproducible manner, suggesting that these TECs could be a viable alternative to pre-formed scaffolds employed through an open surgery for treating bone defects.

KW - METIS-288055

KW - IR-81418

U2 - 10.1089/ten.TEA.2012.0104

DO - 10.1089/ten.TEA.2012.0104

M3 - Article

VL - 19

SP - 340

EP - 349

JO - Tissue engineering. Part A

JF - Tissue engineering. Part A

SN - 1937-3341

IS - 3-4

ER -